Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 5)
Latest Information Update: 23 Mar 2026
At a glance
- Drugs Zenagamtide (Primary)
- Indications Obesity; Osteoarthritis
- Focus Therapeutic Use
- Acronyms AMAZE 5; AMAZE-5
- Sponsors Novo Nordisk
Most Recent Events
- 23 Mar 2026 New trial record